asundexian   Click here for help

GtoPdb Ligand ID: 11710

Synonyms: BAY 2433334 | BAY2433334 | example 235 [WO2017005725A1]
PDB Ligand
Compound class: Synthetic organic
Comment: Asundexian (BAY 2433334) is a small molecule, orally administered coagulation factor XIa inhibitor [1,3-4]. It was developed as a novel anti-thrombotic. The compound's pharmacokinetics support once-daily dosing.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 133.61
Molecular weight 592.12
XLogP 4.61
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES COc1cn(c(=O)cc1c1cc(Cl)ccc1n1nnc(c1)C(F)(F)F)[C@H](C(=O)Nc1ccc(c(c1)F)C(=O)N)CC
Isomeric SMILES O=C(Nc1cc(F)c(C(=O)N)cc1)[C@H](CC)n1cc(OC)c(cc1=O)c1cc(Cl)ccc1n1cc(C(F)(F)F)nn1
InChI InChI=1S/C26H21ClF4N6O4/c1-3-19(25(40)33-14-5-6-15(24(32)39)18(28)9-14)36-11-21(41-2)17(10-23(36)38)16-8-13(27)4-7-20(16)37-12-22(34-35-37)26(29,30)31/h4-12,19H,3H2,1-2H3,(H2,32,39)(H,33,40)/t19-/m0/s1
InChI Key XYWIPYBIIRTJMM-IBGZPJMESA-N
No information available.
Summary of Clinical Use Click here for help
Asundexian (BAY 2433334) has advanced to clinical evaluations for anti-thrombotic potential.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04304508 Study to Gather Information About Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following a Recent Non Cardioembolic Ischemic Stroke Which Occurs When a Blood Clot Has Formed Somewhere in the Human Body (But Not in the Heart) Travelled to the Brain. Phase 2 Interventional Bayer
NCT04510987 Study to Assess the Safety, Tolerability, Effects on the Body, Absorption, Distribution and Elimination of 25 mg BAY2433334 in Renal Impairment Including Renal Replacement Therapy ("Dialysis") Phase 1 Interventional Bayer
NCT05686070 A Study to Learn More About Asundexian (Also Called BAY2433334) for Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older Who Already Had Such a Stroke Due to a Blood Clot That Formed Outside the Heart and Travelled to the Brain, or Temporary Stroke-like Symptoms Phase 3 Interventional Bayer
NCT05643573 A Study to Learn How Well the Study Treatment Asundexian Works and How Safe it is Compared to Apixaban to Prevent Stroke or Systemic Embolism in People With Irregular and Often Rapid Heartbeat (Atrial Fibrillation), and at Risk for Stroke Phase 3 Interventional Bayer Also known as the OCEANIC-AF clinical trial, the first patients were enrolled into NCT05643573 in early 2023.
NCT04218266 Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications. Phase 2 Interventional Bayer Also known as the PACIFIC-AF study, results from NCT04218266 were published in April 2022 [...].
NCT04304534 Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack Phase 2 Interventional Bayer Pharmacodynamics, safety, and efficacy data for asundexian generated from this study was published in October 2022 [...]. The results supported progress to a larger phase 3 study in patients who have experienced an acute myocardial infarction.